About age1
age1 is a venture capital firm founded in 2023. It is primarily based out of San Francisco, United States. As of Feb 2026, age1 is an active investor, having invested in 20 companies, with 3 new investments in the last 12 months. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Loyal Overall, age1 portfolio has seen 1 unicorn, 3 IPOs and 1 acquisition including key companies like Science, ALX Oncology and Precision BioSciences. A lot of funds co-invest with age1, with names like Baillie Gifford sharing a substantial percentage of its portfolio. age1 has team of 6 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
age1's List of Top Investments
age1 has a portfolio of 20 companies, one of which is a Unicorn. Their most notable investments are in Loyal and Aerska.Their portfolio spans across United States and Ireland. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by age1:1. Science
Provider of online science magazine. They specialize in offering content in various topics such as science for patients,technologies and much more.
Key facts about Science
- Founded Year: 2021
- Location: Alameda (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $490M
- Employee Count: 292 as on Apr 30, 2026
- Investors: Lightspeed Venture Partners, Artis Ventures and 7 Others
- Latest Funding Round: Series C, Feb 26, 2026, $*****
- Highlight: Editors' Pick
Developer of therapeutics for age-related diseases. The company uses propriety technology includes the ALEMBIC that focuses on developing medicines to combat biological aging by targeting pathologic cells like senescent ones that drive age-related diseases.
Key facts about RUBEDO LIFE SCIENCES
- Founded Year: 2018
- Location: Sunnyvale (United States)
- Stage: Series A
- Total Funding till date: $52M
- Employee Count: 35 as on Apr 30, 2026
- Investors: Khosla Ventures, The Longevity Fund and 11 Others
- Latest Funding Round: Series A, Apr 22, 2024, $*****
- Highlight: Editors' Pick
_1549346058109.png?format=webp&height=120&width=120){kind=logo}
3. ALX Oncology
Developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.
Key facts about ALX Oncology
- Founded Year: 2015
- Location: Burlingame (United States)
- Annual Revenue: $1.18M as on Dec 31, 2020
- Stage: Public
- Total Funding till date: $123M
- Employee Count: 59 as on Mar 31, 2026
- Investors: BVF Partners, Janus Henderson Investors and 10 Others
- Latest Funding Round: Series C, Feb 12, 2020, $*****
- Highlight: Public
4. Loyal
Provider of therapeutics for the treatment of dogs health. It offers LOY-002 forthe treatment of metabolic dysfunction in large dogs, LOY-001, and LOY-003 for crrecting overexpression of IGF-1 and growth hormone (GH) in large dogs.
Key facts about Loyal
- Founded Year: 2020
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $250M
- Employee Count: 205 as on Mar 31, 2026
- Investors: Baillie Gifford, BoxGroup and 17 Others
- Latest Funding Round: Series C, Feb 11, 2026, $*****
- Highlight: Editors' Pick
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Key facts about Precision BioSciences
- Founded Year: 2006
- Location: Durham (United States)
- Annual Revenue: $34.3M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $136M
- Employee Count: 98 as on Apr 30, 2026
- Investors: Amgen Business Development, RA Capital Management and 29 Others
- Latest Funding Round: Post IPO, Mar 03, 2026, $*****
- Highlight: Public
age1's Year-on-Year Investment Trends
In 2025, it made 3 investments, while as of Feb 2026, it has made 2 investments in this year. Its most recent first time investment was in Loyal and most recent follow-on round was in Aerska.age1's Investments by Stage
age1 has made 2 investments in Seed stage with an average round size of $18.5M, 1 investment in Series A stage with an average round size of $8M and 1 investment in Series C stage with an average round size of $100M.Stage of entry | No. of Investments |
|---|---|
Seed | 2 |
Series A | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
age1's Investments by Sector
age1 has a diverse portfolio, with companies operating in the Life Sciences, HealthTech and High Tech. Notably, it has invested in 17 Tech companies, 16 Enterprise (B2B) companies, 1 Consumer (B2C) company and at least 1 company focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
HealthTech | 2 |
High Tech | 1 |
Note: We have considered here, only first round of investments
age1's Investments by Geography
age1 has made most investments in United States (3), followed by Ireland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 3 |
Ireland | 1 |
Note: We have considered here, only first round of investments
age1's recent investments
age1 has made 2 investments in 2026 so far - Loyal and Aerska.Here are the most recent investments by age1:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 11, 2026 | United States | Series C | 9957 | ||
Feb 09, 2026 | Ireland | Series A | 7296 | [+1] | |
Nov 17, 2025 | United States | Series A | 4820 | [+2] | |
Oct 01, 2025 | Ireland | Seed | 8518 | [+8] | |
Jan 04, 2025 | United States | Seed | 7893 | [+7] |
Unicorns in age1's Portfolio
age1 has 1 unicorn in its portfolio - Science. The most recent unicorn in their portfolio is Science which became a unicorn in 2026.Here is a list of unicorns in age1's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
63 | Provider of online science magazine | 2021 | Alameda | Series C | wknplcy |
IPOs and Publicly Listed companies in age1's Portfolio
3 of age1's portfolio companies have become public. Metacrine got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2020 at marketcap of $85M and ALX Oncology got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are age1's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 15, 2020 | - | - | 6701 | |
Jul 17, 2020 | - | - | 7951 | |
Mar 28, 2019 | - | - | 3152 |
_1549346058109.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in age1's Portfolio
1 company from age1's portfolio has been acquired. The most recent acquisition was Decibel Therapeutics in Aug 2023 by Regeneron Pharmaceuticals for $*****.Here are age1's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 10, 2023 | - | - | 4698 |
Team profile of age1
age1 has a team of 6 members including 2 Partners and 4 Principals located in United States. age1's team does not sit on the board of any company as of now.Here is a list of all team members in age1:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Palo Alto | - | ||
Partner | San Francisco | - | ||
Principal | Boston | - | - | |
Principal | San Francisco | - | ||
Principal | Cambridge | - | ||
Principal | - | - |
Co-investors of age1
Over the past year, 34 investors have co-invested in age1's portfolio companies. This includes funds and angels.
- Invested before age1: Valor Equity Partners, Collab Fund and 8 others have invested in rounds before age1. There is 1 company where Valor Equity Partners has invested before age1 and 1 company where Collab Fund has invested before age1.
- Top Co-investors of age1: 21 investors entered a company along with age1. These include investors like Baillie Gifford (1 company).
- Invested after age1: A total of 3 investors have invested in age1's portfolio after their investments. Top Investors include FreeMind Group (1 company), Daewoong Pharmaceutical (1 company) and Iaso Ventures (1 company).
Recent News related to age1
•
Loyal Raises $100M Series C to Advance First Canine Longevity DrugPet Age•Feb 12, 2026•Loyal, age1, The Longevity Fund, Baillie Gifford
•
Irish BioTech startup Aerska raises €32 million to “enable our loved ones to live longer”EU-Startups•Feb 10, 2026•Aerska, age1, EQT, Iaso Ventures
•
EQT Life Sciences Co-Leads USD 39 Million Series A in AerskaPR Newswire•Feb 09, 2026•Aerska, EQT, Urbaser, age1 and 1 other
•
Skeletalis Raises $8M in FundingFinSMEs•Nov 17, 2025•age1, KdT Ventures, Pillar VC, Skeletalis and 1 other
•
Irish biotech Aerska raises $21m to tackle neurological diseasesBusinessplus•Oct 01, 2025•age1, Backed, Speedinvest, Lingotto and 5 others
•
•
age1 Launches to Advance The Longevity Fund’s Mission to Extend Healthy LifespanBusiness Wire•Sep 19, 2023•age1, The Longevity Fund
